Nicorette Invisi Transdermal Patch

Nicorette Invisi Transdermal Patch Side Effects

nicotine

Manufacturer:

Johnson & Johnson

Distributor:

Zuellig Pharma
Full Prescribing Info
Side Effects
Most of the undesirable effects reported by the subjects occur during the early phase of treatment and are mainly dose-dependent. Allergic reactions (including symptoms of anaphylaxis) occur rarely during use of Nicorette Invisi Transdermal Patch. About 20% of users experienced mild local skin reactions during the 1st weeks of treatment. As would be expected, the types of adverse reactions seen for the Nicorette Invisi Transdermal Patch in clinical trials are similar to those associated with nicotine administered by other means.
Clinical Trial Data: The safety of nicotine from clinical trial data is based on data on a meta-analysis of randomized clinical trials (RCTs) for the treatment of smoking cessation. ADRs with patch formulations identified from clinical trials are presented in Table 3. (See Table 3).

Click on icon to see table/diagram/image

Post-Marketing Data: Adverse drug reactions first identified during post-marketing experience with nicotine are presented in Table 4. Frequencies are provided according to the following convention: Very common ≥1/10; common ≥1/100 and <1/10; uncommon ≥1/1,000 and <1/100; rare ≥1/10,000 and <1/1,000; very rare <1/10,000; not known (cannot be estimated from the available data). (See Table 4).

Click on icon to see table/diagram/image
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in